A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritis
A novel inhibitor of class IIa HDACs has been shown to have an anti-inflammatory and anti-arthritic profile distinct from current therapies. It is efficacious in reducing macrophage infiltration and joint inflammation in a chronic model of rat arthritis.
Authors
- Junxian Lim (ORCID: https://orcid.org/0000-0002-8309-0704)
- Eunice K. Y. Poon (ORCID: https://orcid.org/0000-0002-2577-5481)
- Matthew J. Sweet (ORCID: https://orcid.org/0000-0002-0406-8139)
- David P. Fairlie (ORCID: https://orcid.org/0000-0002-7856-8566)
- Abishek Iyer (ORCID: https://orcid.org/0000-0001-9533-5265)
- Kai‐Chen Wu (ORCID: https://orcid.org/0000-0003-0622-1165)
- Rink‐Jan Lohman (ORCID: https://orcid.org/0000-0001-6387-0992)
- Ligong Liu (ORCID: https://orcid.org/0000-0002-2693-1896)
Institutions
- Australian Research Council (AU)
- The University of Queensland (AU)
- ARC Centre of Excellence for Innovations in Peptide and Protein Science (AU)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/bph.17306
- Citations
- 4
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Imaging Facility
- Australian Cancer Research Foundation
- Medical Research Council
- Australian Research Council
- National Health and Medical Research Council